Victor holds a B.S in biochemistry from the University of Chile (Chile). He completed a PhD in cell biology from the University of the Balearic Islands (Spain) in 2013, providing a novel mechanism to explain the synergistic effect between doxorubicin and nilotinib. These combination was evaluated in a clinical trial showing promising results in soft tissue sarcoma patients. Victor did his first postdoctoral training in France, where he described a non-canonical type of apoptotic cell death triggered by the modulation of metabolic pathways and signaling pathways (mTORC1). During his second postdoc at the Beatson Institute, Glasgow, UK, where he received training in methods to study cancer metabolism (LC-MS/MS) using mouse models of hepatocellular carcinoma. During this time, Victor unmasked an alternative product of glutamine synthetase, N5-methylglutamine, which can be a potential biomarker for specific subset of HCC that express high levels of this enzyme. Victor joined the Mackenzie Institute for early diagnosis in 2023 aiming to identify novel biomarkers for cancer and neurological diseases using untargeted metabolomics (LC-MS/MS) and proteomics.